Shanghai Henlius Biotech, Inc. (HKG: 2696)

Shanghai Henlius Biotech Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Jun 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	649.45	987.67	680.48	707.33	1,114	2,301
Short-Term Investments	16.05	21.7	31.4	34.99	24	25.25
Cash & Short-Term Investments	665.5	1,009	711.87	742.32	1,138	2,326
Cash Growth	-15.15%	41.79%	-4.10%	-34.79%	-51.07%	139.58%
Accounts Receivable	788.86	730.25	455.51	295.74	196.21	29.83
Other Receivables	-	-	160.19	-	-	-
Receivables	788.86	730.25	615.7	295.74	196.21	29.83
Inventory	783.33	757.36	757.31	420.11	305.22	129.87
Other Current Assets	158.87	179.07	106.66	188.99	270.25	174.66
Total Current Assets	2,397	2,676	2,192	1,647	1,910	2,661
Property, Plant & Equipment	2,717	2,653	2,230	1,667	1,437	857.39
Other Intangible Assets	4,820	3,261	2,703	1,919	1,474	399.49
Long-Term Deferred Charges	-	1,250	1,629	1,716	1,469	1,776
Other Long-Term Assets	46.41	64.16	170.61	223.67	149.54	206.58
Total Assets	9,980	9,904	8,924	7,173	6,439	5,900
Accounts Payable	617.15	544.82	713.55	383.47	298.95	240.16
Accrued Expenses	-	975.85	832.73	417.78	259.2	129.87
Short-Term Debt	2,311	2,250	1,839	1,351	923.29	172.27
Current Portion of Long-Term Debt	428.43	463.58	601.62	145.64	193.15	68.43
Current Portion of Leases	98.37	86.96	81.45	74.19	72.04	37.54
Current Income Taxes Payable	-	83.14	20.78	21.64	6.16	2.27
Current Unearned Revenue	381.38	466.88	322.42	138.3	52.23	32.04
Other Current Liabilities	1,067	196.37	589.94	427.86	174.49	277.06
Total Current Liabilities	4,903	5,067	5,002	2,960	1,980	959.64
Long-Term Debt	1,051	1,106	975.29	833.7	424.2	190.43
Long-Term Leases	165.1	186.46	179.65	218.56	220.93	140.72
Long-Term Unearned Revenue	1,209	1,179	839.09	809.68	615.77	608.62
Other Long-Term Liabilities	72.8	172.07	292.37	54.43	-	-
Total Liabilities	7,402	7,711	7,288	4,876	3,240	1,899
Common Stock	543.5	543.5	543.5	543.5	543.5	543.5
Additional Paid-In Capital	6,069	6,069	6,052	6,010	5,954	5,738
Retained Earnings	-3,538	-3,924	-4,470	-3,775	-2,791	-1,798
Comprensive Income & Other	-496.45	-496.11	-488.43	-481.1	-507.78	-483.3
Total Common Equity	2,578	2,192	1,636	2,297	3,199	4,000
Shareholders' Equity	2,578	2,192	1,636	2,297	3,199	4,000
Total Liabilities & Equity	9,980	9,904	8,924	7,173	6,439	5,900
Total Debt	4,054	4,093	3,677	2,623	1,834	609.39
Net Cash (Debt)	-3,389	-3,084	-2,965	-1,881	-695.31	1,717
Net Cash Growth	-	-	-	-	-	287.59%
Net Cash Per Share	-6.23	-5.68	-5.47	-3.49	-1.31	3.45
Filing Date Shares Outstanding	543.49	543.49	543.49	543.49	543.49	543.49
Total Common Shares Outstanding	543.49	543.49	543.49	543.49	543.49	543.49
Working Capital	-2,506	-2,391	-2,810	-1,313	-69.51	1,701
Book Value Per Share	4.74	4.03	3.01	4.23	5.89	7.36
Tangible Book Value	-2,242	-1,068	-1,067	377.41	1,725	3,601
Tangible Book Value Per Share	-4.12	-1.97	-1.96	0.69	3.17	6.63
Buildings	-	629.26	-12,931	-	-	-
Machinery	-	1,047	11,358	859.43	686.3	475
Construction In Progress	-	816.16	1,003	399.69	283.61	37.94
Leasehold Improvements	-	346.79	2,840	295.25	245.7	141.57

Source: S&P Capital IQ. Standard template. Financial Sources.